Photograph of Shannon Lentz

Shannon Lentz

Partner


Companies and innovators looking for creative solutions to complex intellectual property issues trust Shannon Lentz to think outside the box. Whether it is looking for ways to challenge or defend existing patents, or procuring new ones, Shannon has helped craft strategies that mitigate risk and maximize return on intellectual property investments.

Shannon helps clients challenge or defend patents in District Courts as well as before the U.S. Patent and Trademark Office through post-grant review proceedings. She also advises clients looking to avoid adversarial proceedings while still achieving their business goals.

While Shannon’s practice primarily focuses on pharmaceutical technologies, she has wide-ranging experience in cell and molecular biology, genetics, organic chemistry, pharmaceutical chemistry, polymer chemistry, metallurgy, medical devices, biologics, coatings, adhesives, nanomaterials, research tools, and drug delivery technologies.

Prior to becoming a lawyer, Shannon worked in the Functional Genomics group of the Biological Defense Research Directorate of the Naval Medical Research Center, where she sequenced bacterial and viral genomes using next-generation sequencing technologies.

Education

  • University of Maryland School of Law, J.D.
  • University of Maryland, College Park, B.S. Molecular Biology and Genetics

Affiliations

View More

Practices

Intellectual Property Litigation

Intellectual Property

Global IP Law

Post-Grant Proceedings

International Patent

Patent Prosecution

Show more practices…

Industries

Life Sciences

  • Representing LifeNet Health in a five-patent case against Surgalign (f/k/a RTI Surgical) involving soft tissue grafts and spinal implants, successfully defending LifeNet Health’s patents against IPR petitions filed by Surgalign.
  • Represented inventors in a highly contested patent inventorship bench trial in the Central District of California and subsequent appeal to the Federal Circuit involving a pharmaceutical compound.
  • Moderna v. CureVac: Represented patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
  • Apotex v. Amgen, IPR2016-01542 (PTAB): Represented petitioner Apotex in an inter partes review successfully invalidating a patent relating to Neupogen® and Neulasta®.
  • LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal. 
  • Represented university system in patent license dispute over cancer treatment in which the plaintiff pharmaceutical company sought damages exceeding $200 million. Obtained summary adjudication in favor of client.
  • Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
Crowell & Moring Promotes Largest Partner Class In Its History Law360 (January 11, 2023)
Press Coverage
Crowell & Moring Elects 16 New Partners, Promotes Five to Senior Counsel, and 25 to Counsel (January 9, 2023)
Firm News / Announcement
LITIGATION NOTE: Crowell & Moring Secures Preliminary Injunction for Lonza in Ground-Breaking Cell Therapy Patent Infringement Case (January 27, 2022)
Firm News / Announcement
"After Arthrex Decision, Interim USPTO Guidance Allows Straight-to-Director Review of Any Issue in an IPR," IP Insights (July 2, 2021). Contacts: Vincent J. Galluzzo, Shannon Lentz, Laura A. Lydigsen, Joshua James
Client Alert / Newsletter
"Supreme Court’s recent decision in US v. Arthrex found that Section 6(c) of the AIA was unconstitutional," (June 24, 2021). Contacts: Vincent J. Galluzzo, Shannon Lentz
Client Alert / Newsletter
"U.S. Patent Applicants Can Now Expedite Appeals Under New Pilot Program," IP Insights (July 6, 2020). Contacts: Shannon Lentz, Deborah H. Yellin
Client Alert / Newsletter
Apotex Challenges Amgen Cancer Biologic Patent As Obvious Law360 (December 13, 2017)
Press Coverage
Crowell & Moring Elects Six New Partners and Promotes 19 Associates to Counsel (January 9, 2017)
Firm News / Announcement
Litigation Note: Supreme Court of California Denies Appeal in Medivation, Inc. v. Aragon Pharmaceuticals (December 16, 2016)
Firm News / Announcement

For all Highlights, News & Knowledge, please click here to view desktop bio.

Crowell & Moring LLP is an international law firm with offices in the United States, Europe, MENA, and Asia that represents clients in litigation and arbitration, regulatory and policy, and transactional and corporate matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation and government-facing matters, as well as its ongoing commitment to pro bono service and diversity, equity, and inclusion.

View Desktop Site | Mobile Sitemap |

Contact | Subscribe | Terms of Use | Privacy Statement | Alumni

© Crowell & Moring LLP 2023
Attorney advertising - prior results do not guarantee a similar outcome.